Skip to content

Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position

Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral position-a Study Protocol for a Single-centre, Prospective, Randomised Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06572501
Enrollment
200
Registered
2024-08-27
Start date
2023-08-06
Completion date
2030-01-31
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prone Position, Renal Tumor, Robotic Assisted Partial Nephrectomy

Brief summary

The goal of this clinical trial is to investigate whether robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position had any advantages over the traditional lateral position. The main questions it aims to answer are: Is prone surgery safe and feasible, and what are the advantages over the traditional lateral position? Does surgery in the prone position have an impact on the patients' prognosis? Researchers will compare prone position to lateral position to see if robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position has any advantages over the traditional lateral position and whether it has any significant effect on the prognosis of the patients. Participants will be randomly allocated 1:1 to two groups: prone position group and lateral position group. The enrolled patients will be underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach according to the corresponding positions of their groups. Demographic indicators and perioperative-related indicators will be counted and recorded. CT or MRI and related biochemical examinations will be reviewed at 1 month, 3 months, 6 months and 1 year after surgery, and every 1 year thereafter. The similarities and differences of the indicators in different positions will be analysed, and subgroup analyses will be performed according to the corresponding results.

Interventions

PROCEDURERobot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position

This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the prone position

PROCEDURERobot-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position

This group of patients underwent robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach in the lateral position

Sponsors

The First Affiliated Hospital with Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. . Patients with preoperative imaging suggestive of renal occupancy; 2. . Sex is not limited; 3. . Age ≥18 years; 4. . Clinical staging consistent with indications for partial nephrectomy; 5. . Suitable for robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach as judged by relevant preoperative clinical data; 6. . Agree to provide basic clinical information and pathological and imaging data for scientific research and sign an informed consent form; 7. . Agree to provide monitoring results during the follow-up recurrence monitoring process.

Exclusion criteria

1. . Patients who did not meet the indications for partial nephrectomy and did not undergo robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach; 2. . Patients who refuse to undergo or cannot tolerate surgery in the appropriate position; 3. . Patients with incomplete documentation of relevant data to provide accurate demographic, perioperative, and prognostic data; 4. . Any condition which, in the opinion of the investigator, may be detrimental to the subject or result in the inability of the subject to meet or perform the requirements of the study; 5. . Patients who are unable to provide written informed consent;

Design outcomes

Primary

MeasureTime frameDescription
Tumour characteristics checklistBaseline ( before surgery)We will record tumor size (cm), location, position, laterality through preoperative imaging.
Tumour characteristics assessed by RENAL nephrometry scoreBaseline ( before surgery)The R.E.N.A.L. Nephrometry Score consists of (R)adius (tumor size as maximal diameter), (E)xophytic/endophytic properties of the tumor, (N)earness of tumor deepest portion to the collecting system or sinus, (A)nterior (a)/posterior (p) descriptor and the (L)ocation relative to the polar line. The suffix h (hilar) is assigned to tumors that abut the main renal artery or vein. Of the 5 components 4 are scored on a 1, 2 or 3-point scale with the 5th indicating the anterior or posterior location of the mass relative to the coronal plane of the kidney. Higher scores indicate more complex tumour.
Demographics of patientsBaseline ( before surgery)age (year)
Perioperative dataIntraoperative statusintraoperative average PaCO2(mmHg).
postoperative dataPostoperative 3/30/60/90 days and 1/2/3 yearspostoperative estimated glomerular filtration rate(ml/min/1.73m2).
Incidence of postoperative complicationsPostoperative 3/30/60/90 days and 1/2/3 yearsWe will assess the complications by conducting telephone follow-up, as well as reviewing the results of postoperative radiological and laboratory tests. The complications included whether the patients experienced bleeding, infection, urinary fistula and renal insufficiency.
Tumour recurrence or metastasisPostoperative 30/60/90 days and 1/2/3 yearsWe will conduct telephone follow-up and review the results of postoperative radiological tests to see whether tumour recurrence or metastasis occurred.

Countries

China

Contacts

Primary ContactQiang Lu
doctorlvqiang@njmu.edu.cn13505196501

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026